Financial Times Gilead to buy cancer drug developer Arcellx for up to $7.8bn
Deal comes as pharmaceutical groups rush to acquire smaller biotech firms with proven drug pipelines
Deal comes as pharmaceutical groups rush to acquire smaller biotech firms with proven drug pipelines